Neo Ivy Capital Management Purchases 11,369 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Neo Ivy Capital Management boosted its stake in IQVIA by 1,065.5% in Q3, buying 11,369 additional shares to hold 12,436 shares valued at about $2.36 million, according to its SEC filing.
• IQVIA narrowly beat quarterly estimates (EPS $3.42 vs. $3.40; revenue $4.36B vs. $4.24B), set FY2026 EPS guidance of 12.550–12.850, and has a consensus "Moderate Buy" target of $231.13 with roughly 89.62% institutional ownership.

Neo Ivy Capital Management boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1,065.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,436 shares of the medical research company's stock after purchasing an additional 11,369 shares during the quarter. Neo Ivy Capital Management's holdings in IQVIA were worth $2,362,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of IQV. Physician Wealth Advisors Inc. grew its holdings in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company's stock valued at $27,000 after buying an additional 134 shares during the period. Westside Investment Management Inc. increased its position in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company's stock valued at $30,000 after buying an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new stake in IQVIA during the 3rd quarter worth $36,000. Asset Dedication LLC lifted its holdings in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company's stock worth $38,000 after acquiring an additional 168 shares in the last quarter. Finally, Rothschild Investment LLC grew its stake in IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company's stock valued at $42,000 after acquiring an additional 124 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQV stock opened at $174.56 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company's fifty day simple moving average is $207.22 and its 200-day simple moving average is $207.37. The firm has a market cap of $29.62 billion, a PE ratio of 22.21, a P/E/G ratio of 1.72 and a beta of 1.39. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter last year, the firm earned $3.12 earnings per share. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on IQV shares. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $255.00 to $225.00 and set an "overweight" rating on the stock in a report on Friday, February 6th. Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a "buy" rating for the company in a research report on Thursday, February 19th. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a report on Friday, February 6th. Barclays raised shares of IQVIA from an "equal weight" rating to an "overweight" rating and set a $210.00 target price for the company in a research note on Friday. Finally, Morgan Stanley set a $240.00 target price on IQVIA in a report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $231.13.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.